Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stig Hansen

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Health Security|August 3, 2016
A Biosecurity Survey in Kenya, November 2014 to February 2015Edwardina Otieno Ndhine, Hans-Christian Slotved, Eric Mogaka Osoro, et al.
American Journal of Medical Genetics. Part A|June 30, 2016
Neurophysiology versus clinical genetics in Rett syndrome: A multicenter studyNicky Halbach, Eric E Smeets, Peter Julu, et al.
BMJ (Clinical Research Ed.)|December 13, 2005
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialChristian M Jespersen, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Cardiovascular Pharmacology|November 19, 2009
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart diseaseGorm B Jensen, Jørgen Hilden, Bodil Als-Nielsen, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trialJørgen Hilden, Inga Lind, Hans Jørn Kolmos, et al.
Cardiology|May 3, 2008
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart diseaseChristian Gluud, Bodil Als-Nielsen, Morten Damgaard, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Neuropediatrics|March 21, 2012
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 casesGiorgio Pini, Stefania Bigoni, Ingegerd Witt Engerström, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Health Security|August 3, 2016
A Biosecurity Survey in Kenya, November 2014 to February 2015Edwardina Otieno Ndhine, Hans-Christian Slotved, Eric Mogaka Osoro, et al.
American Journal of Medical Genetics. Part A|June 30, 2016
Neurophysiology versus clinical genetics in Rett syndrome: A multicenter studyNicky Halbach, Eric E Smeets, Peter Julu, et al.
BMJ (Clinical Research Ed.)|December 13, 2005
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialChristian M Jespersen, Bodil Als-Nielsen, Morten Damgaard, et al.
Journal of Cardiovascular Pharmacology|November 19, 2009
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart diseaseGorm B Jensen, Jørgen Hilden, Bodil Als-Nielsen, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trialJørgen Hilden, Inga Lind, Hans Jørn Kolmos, et al.
Cardiology|May 3, 2008
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart diseaseChristian Gluud, Bodil Als-Nielsen, Morten Damgaard, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Neuropediatrics|March 21, 2012
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 casesGiorgio Pini, Stefania Bigoni, Ingegerd Witt Engerström, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Pageof 4